• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

A marker of aggressive liver cancer and potential therapeutic target identified

bys25qthea
June 13, 2013
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Patients whose liver cancers had higher levels of SALL4 had a poorer prognosis.

2. SALL4 could be a therapeutic target.

Study Rundown: SALL4 encodes a transcription factor that is a known leukemia oncogene. In mouse models, SALL4 expression correlates with an embryonic progenitor cell-like pattern of gene expression. The gene is highly expressed in the fetal mouse liver, but expression gradually decreases and disappears by adulthood. In light of this, the authors hypothesized that inappropriate expression of SALL4 in adult hepatocytes might play a role in progenitor-like hepatocellular carcinomas, an aggressive subset of liver cancers.

The authors show that tissue samples of hepatocellular carcinomas with higher SALL4 expression were correlated with poorer survival. The high-SALL4 samples were enriched for genes in pathways known to be associated with worse prognosis. As this was a retrospective study, the prognostic value of SALL4 should be further evaluated in prospective trials.

The authors are enthusiastic about SALL4 as a therapeutic target because it is not expressed in normal adult tissues. The therapeutic window of a SALL4 inhibitor should therefore be quite large. In the study, the authors show that a small peptide inhibitor of SALL4 inhibits the tumorigenicity of a high-SALL4 tumor cell line both in vitro and in mouse models.

Click to read the study in the New England Journal of Medicine

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

Monthly subsidy increased purchase of fresh fruits and vegetables in Supplemental Nutrition Assistance Program beneficiaries

Relevant Reading: Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex

In-Depth [retrospective study]: Tissue specimens of hepatocellular carcinomas from patients in Singapore and Hong Kong were analyzed for gene expression patterns via microarray. Full clinicopathological data was available for 79 samples in the Singapore specimens, allowing comparison of survival between patients with high and low-SALL4 tumors. Samples with SALL4 levels that were equal to or exceeded median SALL4 expression were classified as high-SALL4. High-SALL4 was correlated with poorer survival.

In order to explore SALL4 as a therapeutic target, the authors transplanted a high-SALL4 tumor cell line into mice and introduced a small peptide inhibitor of SALL4. The tumor load after 18 days was less in mice that received the peptide compared to mice that received a control (0.5g vs. 1.5g, p <0.05). The authors also show that the peptide does not inhibit the growth of a low-SALL4 tumor cell line, illustrating the selective toxicity of SALL4 inhibition.

By Tomi Jun and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: healthliver cancerSALL4
Previous Post

Elevated inflammatory biomarkers linked with increased risk of COPD exacerbations

Next Post

On-demand inhalation treatment for bronchiolitis is superior to fixed schedule treatment

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital
Wellness

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

May 20, 2022
Vegetarian diet may lower incidence of colorectal cancer
Wellness

Monthly subsidy increased purchase of fresh fruits and vegetables in Supplemental Nutrition Assistance Program beneficiaries

October 18, 2021
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival
Gastroenterology

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

August 31, 2020
Next Post
On-demand inhalation treatment for bronchiolitis is superior to fixed schedule treatment

On-demand inhalation treatment for bronchiolitis is superior to fixed schedule treatment

Reducing surgical complications may increase costs

Postoperative complications linked with unplanned hospital readmissions

Complications 4.5x more frequent in hernias repaired laparoscopically vs. open repair

Laparoscopic splenectomy yields better outcomes than open

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors associated with breastfeeding rates in Canada
  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options